PMID- 21633921
OWN - NLM
STAT- MEDLINE
DCOM- 20120112
LR  - 20211020
IS  - 1861-0692 (Electronic)
IS  - 1861-0684 (Linking)
VI  - 100
IP  - 10
DP  - 2011 Oct
TI  - Transplantation of progenitor cells and regeneration enhancement in acute 
      myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term 
      safety and efficacy.
PG  - 925-34
LID - 10.1007/s00392-011-0327-y [doi]
AB  - BACKGROUND: Limited data is available for investigating the long-term safety and 
      effects of intracoronary progenitor cell therapy in patients with acute 
      myocardial infarction (AMI). OBJECTIVE: To assess the clinical course, NT-proBNP 
      and MRI data as objective markers of cardiac function of the TOPCARE-AMI patients 
      at 5-year follow-up. DESIGN: The TOPCARE-AMI trial was the first randomized study 
      investigating the effects of intracoronary infusion of circulating (CPC) or bone 
      marrow-derived progenitor cells (BMC) in 59 patients with successfully reperfused 
      AMI. RESULTS: Five-year follow-up data were completed in 55 patients, 3 patients 
      were lost to follow-up. None of the patients showed any signs of intramyocardial 
      calcification or tumors at 5 years. One patient died during the initial 
      hospitalization, no patient was rehospitalized for heart failure and 16 patients 
      underwent target vessel revascularization (TVR). Only two TVRs occurred later 
      than 1 year after cell administration making it very unlikely that the infused 
      cells accelerate atherosclerotic disease progression. Serum levels of NT-proBNP 
      remained significantly reduced at the 5-year follow-up indicating the absence of 
      heart failure. MRI subgroup analysis in 31 patients documented a persistent 
      improvement of LV ejection fraction (from 46 +/- 10% at baseline to 57 +/- 10% at 
      5 years, p < 0.001)). Simultaneously, there was a reduction (p < 0.001) in 
      functional infarct size measured as late enhancement volume normalized to LV 
      mass. However, whereas LV end-systolic volume remained stable, LV end-diastolic 
      volume increased significantly. CONCLUSIONS: The 5-year follow-up of the 
      TOPCARE-AMI trial provides reassurance with respect to the long-term safety of 
      intracoronary cell therapy and suggests favorable effects on LV function.
FAU - Leistner, David M
AU  - Leistner DM
AD  - Division of Cardiology, Department of Medicine III, Goethe University Frankfurt, 
      Germany.
FAU - Fischer-Rasokat, Ulrich
AU  - Fischer-Rasokat U
FAU - Honold, Jorg
AU  - Honold J
FAU - Seeger, Florian H
AU  - Seeger FH
FAU - Schachinger, Volker
AU  - Schachinger V
FAU - Lehmann, Ralf
AU  - Lehmann R
FAU - Martin, Hans
AU  - Martin H
FAU - Burck, Iris
AU  - Burck I
FAU - Urbich, Carmen
AU  - Urbich C
FAU - Dimmeler, Stefanie
AU  - Dimmeler S
FAU - Zeiher, Andreas M
AU  - Zeiher AM
FAU - Assmus, Birgit
AU  - Assmus B
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110603
PL  - Germany
TA  - Clin Res Cardiol
JT  - Clinical research in cardiology : official journal of the German Cardiac Society
JID - 101264123
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adult
MH  - *Angioplasty, Balloon, Coronary/adverse effects/instrumentation/mortality
MH  - Biomarkers/blood
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Germany
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Magnetic Resonance Imaging
MH  - Middle Aged
MH  - Myocardial Infarction/blood/mortality/pathology/physiopathology/*therapy
MH  - Myocardium/*pathology
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Recovery of Function
MH  - *Regeneration
MH  - *Stem Cell Transplantation/adverse effects/mortality
MH  - Stents
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left
EDAT- 2011/06/03 06:00
MHDA- 2012/01/13 06:00
CRDT- 2011/06/03 06:00
PHST- 2010/12/02 00:00 [received]
PHST- 2011/05/23 00:00 [accepted]
PHST- 2011/06/03 06:00 [entrez]
PHST- 2011/06/03 06:00 [pubmed]
PHST- 2012/01/13 06:00 [medline]
AID - 10.1007/s00392-011-0327-y [doi]
PST - ppublish
SO  - Clin Res Cardiol. 2011 Oct;100(10):925-34. doi: 10.1007/s00392-011-0327-y. Epub 
      2011 Jun 3.